De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
United Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 3/6
United Therapeutics is de winst gegroeid met een gemiddeld jaarlijks percentage van 34.9%, terwijl de Biotechs industrie de winst jaarlijks groeide met 19.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 12.2% per jaar. Het rendement op eigen vermogen van United Therapeutics is 18.8%, en het heeft een nettomarge van 40.9%.
Belangrijke informatie
34.9%
Groei van de winst
33.8%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | 12.2% |
| Rendement op eigen vermogen | 18.8% |
| Nettomarge | 40.9% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27
United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely
Jul 17Opbrengsten en kosten
Hoe United Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 2,617 | 1,069 | 581 | 480 |
| 31 Mar 24 | 2,498 | 1,051 | 533 | 429 |
| 31 Dec 23 | 2,328 | 985 | 476 | 408 |
| 30 Sep 23 | 2,204 | 900 | 499 | 351 |
| 30 Jun 23 | 2,111 | 872 | 470 | 332 |
| 31 Mar 23 | 1,981 | 728 | 481 | 337 |
| 31 Dec 22 | 1,936 | 727 | 473 | 323 |
| 30 Sep 22 | 1,860 | 707 | 448 | 312 |
| 30 Jun 22 | 1,789 | 631 | 458 | 324 |
| 31 Mar 22 | 1,768 | 687 | 429 | 304 |
| 31 Dec 21 | 1,686 | 476 | 466 | 410 |
| 30 Sep 21 | 1,655 | 462 | 499 | 450 |
| 30 Jun 21 | 1,591 | 471 | 451 | 440 |
| 31 Mar 21 | 1,506 | 405 | 444 | 456 |
| 31 Dec 20 | 1,483 | 515 | 421 | 358 |
| 30 Sep 20 | 1,410 | 469 | 364 | 345 |
| 30 Jun 20 | 1,431 | 430 | 402 | 362 |
| 31 Mar 20 | 1,443 | 528 | 336 | 350 |
| 31 Dec 19 | 1,449 | -104 | 335 | 1,174 |
| 30 Sep 19 | 1,519 | -92 | 313 | 1,199 |
| 30 Jun 19 | 1,530 | -118 | 324 | 1,214 |
| 31 Mar 19 | 1,601 | -150 | 367 | 1,220 |
| 31 Dec 18 | 1,628 | 589 | 269 | 358 |
| 30 Sep 18 | 1,711 | 543 | 348 | 333 |
| 30 Jun 18 | 1,744 | 713 | 285 | 287 |
| 31 Mar 18 | 1,744 | 484 | 270 | 264 |
| 31 Dec 17 | 1,725 | 418 | 333 | 265 |
| 30 Sep 17 | 1,670 | 509 | 311 | 218 |
| 30 Jun 17 | 1,632 | 395 | 363 | 209 |
| 31 Mar 17 | 1,600 | 657 | 368 | 184 |
| 31 Dec 16 | 1,599 | 714 | 319 | 148 |
| 30 Sep 16 | 1,595 | 708 | 326 | 157 |
| 30 Jun 16 | 1,573 | 1,011 | 209 | 120 |
| 31 Mar 16 | 1,507 | 904 | 246 | 135 |
| 31 Dec 15 | 1,466 | 652 | 453 | 245 |
| 30 Sep 15 | 1,407 | 663 | 385 | 241 |
| 30 Jun 15 | 1,351 | 173 | 604 | 350 |
| 31 Mar 15 | 1,327 | 186 | 562 | 340 |
| 31 Dec 14 | 1,289 | 340 | 381 | 243 |
| 30 Sep 14 | 1,231 | 194 | 458 | 293 |
| 30 Jun 14 | 1,203 | 282 | 350 | 246 |
| 31 Mar 14 | 1,161 | 250 | 353 | 261 |
| 31 Dec 13 | 1,117 | 175 | 394 | 299 |
Kwaliteitswinsten: UTHR heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (40.9%) UTHR } zijn lager dan vorig jaar (41.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: UTHR is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 34.9% per jaar laten groeien.
Versnelling van de groei: De winstgroei van UTHR over het afgelopen jaar ( 22.7% ) ligt onder het 5-jarig gemiddelde ( 34.9% per jaar).
Winst versus industrie: De winstgroei UTHR over het afgelopen jaar ( 22.7% ) overtrof de Biotechs -sector 0.5%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 18.8% ) van UTHR wordt als laag beschouwd.